Journal
IMMUNOLOGICAL REVIEWS
Volume 225, Issue -, Pages 244-255Publisher
WILEY
DOI: 10.1111/j.1600-065X.2008.00689.x
Keywords
bacterial; lung; immunotherapies; phagocytosis; Fc receptors; antibodies
Categories
Funding
- NIH [PO1 AI056320, U54 AI057158]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158, P01AI056320] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Francisella tularensis can cause fatal respiratory tularemia in humans and animals and is increasingly being isolated in the United States and several European countries. The correlates of protective immunity against this intracellular bacterium are not known, and currently there are no licensed vaccines available for human use. Cell-mediated immunity has long been believed to be critical for protection, and the importance of humoral immunity is also now recognized. Furthermore, synergy between antibodies, T cell-derived cytokines, and phagocytes appears to be critical to achieve sterilizing immunity against F. tularensis. Thus, novel vaccine approaches should be designed to induce robust antibody and cell-mediated immune responses to this pathogen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available